Advertisement
Advertisement

TheBody.com/TheBodyPRO.com covers The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)

Reyataz and Kidney Stones

November/December 2012

Reyataz, one of two preferred HIV protease inhibitor (PI) medications under U.S. treatment guidelines, is associated with the risk of kidney stones and other potential renal abnormalities. According to Japanese researchers, people taking Norvir-boosted Reyataz developed kidney stones 10 times more frequently than those taking other PIs. Kidney stones were diagnosed in 31 of 465 individuals on boosted Reyataz vs. four out of 775 patients taking another PI.

Furthermore, six of the 18 people who continued taking boosted Reyataz after developing kidney stones experienced new ones. Lead researcher Yohei Hamada, M.D., pointed out that most participants were of East Asian origin and, "Thus, it will be important to investigate the association between [Norvir-boosted Reyataz] and the development of renal stones in other populations."

The study was conducted at the National Center for Global Health and Medicine in Tokyo.


Got a comment on this article? Write to us at publications@tpan.com.



This article was provided by Positively Aware. It is a part of the publication Positively Aware. Visit Positively Aware's website to find out more about the publication.
 


 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement